Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| lymphocyte function-associated antigen 3 receptors | 5088 | 222535-22-0 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 30, 2003 | FDA | ASTELLAS |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Carotid artery thrombosis | 653.06 | 510.61 | 154 | 8097 | 8938 | 90611258 |
| Neurologic neglect syndrome | 651.98 | 510.61 | 153 | 8098 | 8694 | 90611502 |
| Adjustment disorder | 638.88 | 510.61 | 153 | 8098 | 9489 | 90610707 |
| Personality disorder | 600.10 | 510.61 | 153 | 8098 | 12291 | 90607905 |
| Skin haemorrhage | 557.80 | 510.61 | 162 | 8089 | 21218 | 90598978 |
| Hemiplegia | 555.80 | 510.61 | 152 | 8099 | 16008 | 90604188 |
| Affect lability | 548.15 | 510.61 | 154 | 8097 | 17909 | 90602287 |
| Sensory loss | 543.49 | 510.61 | 153 | 8098 | 17922 | 90602274 |
| Motor dysfunction | 534.12 | 510.61 | 153 | 8098 | 19077 | 90601119 |
| Gangrene | 531.93 | 510.61 | 140 | 8111 | 12736 | 90607460 |
| Arterial occlusive disease | 531.81 | 510.61 | 139 | 8112 | 12307 | 90607889 |
| Coordination abnormal | 522.65 | 510.61 | 154 | 8097 | 21202 | 90598994 |
| Sinus congestion | 518.01 | 510.61 | 162 | 8089 | 27262 | 90592934 |
| Respiratory tract congestion | 513.90 | 510.61 | 161 | 8090 | 27249 | 90592947 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neurologic neglect syndrome | 682.70 | 505.15 | 155 | 8249 | 9143 | 110571752 |
| Carotid artery thrombosis | 682.53 | 505.15 | 156 | 8248 | 9482 | 110571413 |
| Adjustment disorder | 659.67 | 505.15 | 155 | 8249 | 10640 | 110570255 |
| Personality disorder | 632.97 | 505.15 | 155 | 8249 | 12682 | 110568213 |
| Affect lability | 580.33 | 505.15 | 156 | 8248 | 18481 | 110562414 |
| Skin haemorrhage | 571.73 | 505.15 | 164 | 8240 | 24663 | 110556232 |
| Sensory loss | 553.99 | 505.15 | 155 | 8249 | 21302 | 110559593 |
| Hemiplegia | 540.29 | 505.15 | 154 | 8250 | 22628 | 110558267 |
| Sinus congestion | 538.62 | 505.15 | 164 | 8240 | 30295 | 110550600 |
| Arterial occlusive disease | 537.78 | 505.15 | 141 | 8263 | 15167 | 110565728 |
| Sneezing | 534.96 | 505.15 | 165 | 8239 | 31819 | 110549076 |
| Motor dysfunction | 534.24 | 505.15 | 155 | 8249 | 24251 | 110556644 |
| Coordination abnormal | 533.59 | 505.15 | 156 | 8248 | 25072 | 110555823 |
| Gangrene | 533.40 | 505.15 | 142 | 8262 | 16199 | 110564696 |
| Respiratory tract congestion | 532.26 | 505.15 | 163 | 8241 | 30694 | 110550201 |
| Sinus disorder | 527.01 | 505.15 | 164 | 8240 | 32564 | 110548331 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AA15 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants |
| FDA CS | M0018640 | Recombinant Fusion Proteins |
| FDA CS | M0028142 | Immunoconjugates |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D007155 | Immunologic Factors |
| FDA MoA | N0000175857 | CD2-directed Antibody Interactions |
| FDA EPC | N0000175859 | CD2-directed LFA-3/Fc Fusion Protein |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Plaque psoriasis | indication | 200965009 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| T-cell surface antigen CD2 | Surface antigen | INHIBITOR | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| ELK3V90G6C | UNII |
| D02800 | KEGG_DRUG |
| 4021373 | VANDF |
| C0962603 | UMLSCUI |
| CHEBI:749492 | CHEBI |
| CHEMBL1201571 | ChEMBL_ID |
| DB00092 | DRUGBANK_ID |
| D000077944 | MESH_DESCRIPTOR_UI |
| 8059 | INN_ID |
| 6787 | IUPHAR_LIGAND_ID |
| 299635 | RXNORM |
| 17114 | MMSL |
| 46117 | MMSL |
| d04843 | MMSL |
| 009880 | NDDF |
| 398691006 | SNOMEDCT_US |
| 398857009 | SNOMEDCT_US |
None